Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Inclusion Criteria: * Joined the study voluntarily and signed informed consent form; * Age 18-75 years; both genders * Esophageal squamous cell carcinoma confirmed by pathology. * No radiotherapy, chemotherapy or other treatments prior to enrollment * Locally advanced esophageal squamous cell carcinoma (T1N1-3M0, T2-4NxM0, TxNxM1 (supraclavicular lymph node metastasis only) (AJCC 8th) * Use of an effective contraceptive for adults to prevent pregnancy. * No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function. No immunodeficiency. * WBC ≥ 3.5\*109/L, Hemoglobin ≥ 9 g/dL, Neutrophils ≥ 1·5\*109/L, Platelet count ≥ 100\*109/L, ALAT and ASAT \< 2·5 \* ULN, TBIL \< 1·5 \* ULN, and Creatinine \< 1·5 \*ULN. * ECOG 0-2. * Life expectancy of more than 3 months. * Agreement of PET/CT accessment at 25-28 radiotherapy fraction. Exclusion Criteria: * Total radiotherapy dose cannot reach 61.2Gy/34Fx in the condition of the nomal tissue dose complying to the standard criteria. * Esophageal perforation, or hematemesis. * History of radiotherapy or chemotherapy for esophageal cancer. * History of surgery within 28 days before Day 1. * History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years). * Participation in other interventional clinical trials within 30 days. * Pregnant or breast-feeding women or fertile patients who refused to use contraceptives. * Drug addiction, alcoholism or AIDS. * Uncontrolled seizures or psychiatric disorders. * Any other condition which in the investigator's opinion would not make the patient a good candidate for the clinical trial.